OXURION (EBR:OXUR) | WebDisclosure

Basculer en Français

9815	Companies
196953	Keywords
128003	Articles
104734	Press releases

Home
Companies
OXURION

PRESS RELEASE

published on 08/07/2025 at 18:00, 5 months 29 days ago

Oxurion beëindigt RD-programma voor geografische maculaire degeneratie en focust op nieuwe CRO-activiteiten
Oxurion beendet präklinisches Forschungsprogramm zur Entwicklung neuer Therapieziele für altersbedingte Makuladegeneration (GA) und fokussiert auf CRO-Aktivitäten und Profitabilität. Integrierte Datenexpertise und externe Expansion im Fokus

Profitabilität Oxurion Präklinisches Forschungsprogramm GA CRO-Aktivitäten
PRESS RELEASE

published on 08/07/2025 at 18:00, 5 months 29 days ago

Oxurion Receives Transparency Notifications from UBS Group AG
Oxurion NV received transparency notifications from UBS Group AG regarding share holdings, in compliance with Belgian Transparency legislation. The company is a biopharmaceutical group focusing on therapeutic innovation and clinical research technologies

Clinical Research Biopharmaceutical UBS Group AG Oxurion NV Transparency Notifications
PRESS RELEASE

published on 08/07/2025 at 18:00, 5 months 29 days ago

Oxurion ontvangt transparantiekennisgevingen van UBS Group AG
Oxurion NV (Euronext Brussel: OXUR) ontvangt transparantiekennisgevingen van UBS Group AG over aandelentransacties conform Belgische wetgeving. Oxurion, biofarmaceutisch bedrijf in Leuven, België, integreert innovatie en klinisch onderzoekstechnologieën

Transparantiekennisgevingen UBS Group AG Oxurion NV Biofarmaceutisch Belgische Wetgeving
BRIEF

published on 08/06/2025 at 18:05, 5 months 30 days ago

Oxurion reçoit des notifications de transparence d'Atlas Special Opportunities II LLC

Actionnariat Transparence Biopharmaceutique Oxurion Opportunités Spéciales Atlas
BRIEF

published on 08/06/2025 at 18:05, 5 months 30 days ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

Transparency Biopharmaceutical Shareholding Atlas Special Opportunities Oxurion
PRESS RELEASE

published on 08/06/2025 at 18:00, 5 months 30 days ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
Oxurion NV receives transparency notifications regarding changes in shareholding from Atlas Special Opportunities II, LLC as per Belgian Transparency legislation. Company combines therapeutic innovation with technology for new treatments

Clinical Research Shareholding Changes Oxurion NV Therapeutic Innovation Transparency Notifications
PRESS RELEASE

published on 08/06/2025 at 18:00, 5 months 30 days ago

Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
Oxurion NV ontvangt transparantiekennisgevingen over aandelentransacties en stimuleert therapeutische innovatie in biofarmaceutica. Zie voor meer informatie www.oxurion.com

Aandelentransacties Transparantiekennisgevingen Oxurion NV Therapeutische Innovatie Biofarmaceutica
BRIEF

published on 08/04/2025 at 18:05, 6 months 1 day ago

Oxurion Sécurise 30 M EUR Pour Diversification en Actifs Numériques

Investissement Financement Biopharmaceutique Cryptomonnaies Oxurion
BRIEF

published on 08/04/2025 at 18:05, 6 months 1 day ago

Oxurion Secures EUR 30M for Diversification into Digital Assets

Funding Investment Cryptocurrencies Biopharmaceuticals Oxurion
PRESS RELEASE

published on 08/04/2025 at 18:00, 6 months 1 day ago

Oxurion obtient une offre de financement revue à la hausse à 30 M EUR pour lancer la diversification de sa trésorerie en actifs numériques
Oxurion NV reçoit une offre de financement de 30 millions d'euros d'Atlas Special Opportunities pour investir dans Bitcoin et Ethereum. Objectif de diversification de la trésorerie

Financement Bitcoin Ethereum Oxurion NV 30 Millions D'euros

Accesswire

Published on 02/06/2026 at 08:00, 39 minutes ago

Caledonia Mining Corporation Plc Non-Executive Director Shareholding Notification
Published on 02/06/2026 at 03:50, 4 hours 49 minutes ago

High Tide Resources annonce des placements privés sans courtier
Published on 02/06/2026 at 02:45, 5 hours 54 minutes ago

High Tide Resources annonce des placements privés sans courtier
Published on 02/06/2026 at 00:57, 7 hours 42 minutes ago

Noram Lithium Announces Closing of Fully Allocated Non-Brokered Financing
Published on 02/06/2026 at 00:00, 8 hours 39 minutes ago

LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories

View all ACCESSWIRE

EQS Group

Published on 02/06/2026 at 08:15, 24 minutes ago

Bechtle posts strong year-end performance
Published on 02/06/2026 at 08:00, 39 minutes ago

A stronger and more competitive Ørsted after a defining year with earnings of DKK 25.1 billion within guidance
Published on 02/06/2026 at 08:00, 39 minutes ago

Transaction in Own Shares
Published on 02/06/2026 at 08:00, 39 minutes ago

BIOSYNEX SA: CHEMBIO DIAGNOSTIC SYSTEMS INC., FILIALE DE BIOSYNEX, REÇOIT UNE SUBVENTION DE $1,8 MILLION DE CARB-X POUR LE DÉVELOPPEMENT D'UN TEST DE DIAGNOSTIC RAPIDE DE LA FIEVRE TYPHOIDE
Published on 02/06/2026 at 07:30, 1 hour 9 minutes ago

Nordex Group wins multiple European contracts totaling 220 MW in January 2026

Les Echos

Published on 02/06/2026 at 07:54, 44 minutes ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026
Published on 02/05/2026 at 19:24, 13 hours 14 minutes ago

Minutes of the Combined General Meeting
Published on 02/05/2026 at 19:24, 13 hours 14 minutes ago

Compte-Rendu de l’Assemblée Générale Mixte
Published on 02/05/2026 at 19:15, 13 hours 24 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 02/05/2026 at 19:15, 13 hours 24 minutes ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES JANVIER 2026

View all LES ECHOS COMFI WIRE